Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Byooviz (ranibizumab) (Samsung Bioepis / Biogen) (March-2022)
Biosimilars Approved In The E.U.
Benepali (etanercept) (Samsung Bioepis / Biogen) (January-2016)Byooviz (ranibizumab) (Samsung Bioepis / Biogen) (August-2021)Tofidence (tocilizumab) (Biogen / Bio-Thera) (June-2024)
Biosimilars Approved In South Korea
Amelivu (ranibizumab) (Samsung Bioepis) (May-2022)
Inter Partes Review Proceedings
RITUXANIPR2015-00415IPR2015-00418IPR2015-01744IPR2016-01614IPR2017-01093IPR2017-01094IPR2017-01095IPR2017-01115IPR2017-01166IPR2017-01167IPR2017-01168IPR2017-01227IPR2017-01229IPR2017-01230IPR2017-02126IPR2017-02127IPR2018-00086IPR2018-00186IPR2018-00231IPR2018-00285TYSABRIIPR2016-00912IPR2016-00915IPR2016-00916PGR2022-00054RITUXAN / RUXIENCEIPR2017-01115IPR2017-01166IPR2017-01167IPR2017-01168IPR2017-02126IPR2017-02127IPR2018-00086IPR2018-00186IPR2018-00231IPR2018-00285RITUXAN / TRUXIMAIPR2015-01744IPR2016-01614IPR2017-01093IPR2017-01094IPR2017-01095IPR2017-01227IPR2017-01229IPR2017-01230TYSABRI / TYRUKOPGR2022-00054
U.S. Patent Litigations
ADUHELM1:20-cv-10543 (D. Mass.)ACTEMRA / TOFIDENCE1:23-cv-11573 (D. Mass.)ACTIVASE / CATHFLO ACTIVASE / AVASTIN / HERCEPTIN / PULMOZYME / RITUXAN / TNKASE / XOLAIR3:08-cv-04909 (N.D. Cal.)3:09-cv-04919 (N.D. Cal.)AVONEX / BETASERON / EXTAVIA / REBIF2:10-cv-02734 (D.N.J.)2:10-cv-02760 (D.N.J.)RITUXAN / DRL_RI1:23-cv-22485 (D.N.J.)RITUXAN / RIXATHON / GENENTECH CABILLY1:17-cv-13507 (D.N.J.)RITUXAN / TRUXIMA / GENENTECH CABILLY1:18-cv-00574 (D.N.J.)1:18-cv-11553 (D.N.J.)4:18-cv-00276 (N.D. Cal.)SOLIRIS / SYNAGIS / TYSABRI1:11-cv-00084 (D. Del.)TYSABRI / TYRUKO1:22-cv-01190 (D. Del.)